Diabetes medication appears to slow progress of Parkinson's disease in French-backed trialMarket Watch • 04/04/24
Kymera Therapeutics: Advancing Into Phase 2 With Partner Sanofi - I Still Have FaithSeeking Alpha • 03/21/24
Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitisGlobeNewsWire • 03/11/24
Astra-Sanofi's RSV therapy 'highly effective' against infant hospitalizations, CDC study showsReuters • 03/07/24
Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticariaGlobeNewsWire • 02/24/24
Press Release: Filing of the 2023 U.S. Form 20-F and French “Document d'Enregistrement Universel” containing the Annual Financial ReportGlobeNewsWire • 02/23/24
Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammationGlobeNewsWire • 02/23/24
Press Release: Sanofi's Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent DirectorsGlobeNewsWire • 02/22/24
Sanofi's consumer healthcare spin-off attracts private equity interest, sources sayReuters • 02/20/24
Press Release: Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU)GlobeNewsWire • 02/16/24